Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaJeffrey E. Lancet, Maria R. Baer, Michael Burton et al.|Leukemia|2010Cited by 155